Oceania Healthcare (ASX:OCA) has released its interim results for the fiscal period ending September 30, 2024. The company, led by newly appointed CEO Suzanne Dvorak, highlights strategic priorities such as selling unsold stock and reducing debt. The results show growth in operational cash flow and underlying earnings, mainly driven by new Occupation Right Agreement receipts.
Oceania Healthcare's interim results show significant progress under new leadership, with increased EBITDA and ORA receipts. The company is focused on selling unsold stock and reducing debt, pausing dividend distribution until financial targets are met. With plans for expanding villa developments and enhancing sustainability, Oceania aims for a balanced portfolio of care suites and independent living units. The emphasis remains on clinical excellence and sustainable growth as the company navigates a challenging market environment.
Under the leadership of CEO Suzanne Dvorak, we are seeing positive shifts in our financial and operational metrics. The increase in ORA receipts and underlying EBITDA are particularly encouraging. Our focus remains on strategic sales, debt reduction, and enhancing our service offerings to deliver sustainable growth.